Figure 3 | Scientific Reports

Figure 3

From: PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection

Figure 3

Kaplan–Meier survival curves of recurrence-free survival (RFS) in relation to PD-L1 expression based on PD-L1 antibody-IHC assays in patients with breast cancer. (a) Patients with negative PD-L1 expression based on the 22C3-IHC assay were associated with poor RFS (HR 2.537, 95% CI 1.188–5.421, P = 0.0337, log-rank test). (b, c) PD-L1 expression with SP142- and SP263-IHC assays did not show significantly different RFS.

Back to article page